Amgen Inc. (NASDAQ:AMGN) Shares Sold by Shilanski & Associates Inc.

Shilanski & Associates Inc. decreased its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 5.3% in the 4th quarter, Holdings Channel reports. The fund owned 1,080 shares of the medical research company’s stock after selling 60 shares during the period. Shilanski & Associates Inc.’s holdings in Amgen were worth $311,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AMGN. Vanguard Group Inc. increased its position in Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after acquiring an additional 165,636 shares during the period. Morgan Stanley lifted its holdings in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. Geode Capital Management LLC grew its position in Amgen by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 11,799,183 shares of the medical research company’s stock valued at $2,613,646,000 after buying an additional 368,924 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Amgen by 1.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after buying an additional 94,565 shares during the period. Finally, Moneta Group Investment Advisors LLC lifted its stake in shares of Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after acquiring an additional 7,532,031 shares during the period. Hedge funds and other institutional investors own 74.44% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $270.90 on Tuesday. The company has a market capitalization of $145.18 billion, a PE ratio of 21.69, a P/E/G ratio of 2.54 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a 50 day simple moving average of $293.86 and a two-hundred day simple moving average of $279.74.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.09 EPS. Research analysts anticipate that Amgen Inc. will post 19.48 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Analyst Ratings Changes

Several brokerages have recently weighed in on AMGN. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a report on Tuesday. Oppenheimer reissued an “outperform” rating and set a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Truist Financial reiterated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Wednesday, November 29th. UBS Group reduced their target price on Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a report on Monday, January 29th. Finally, Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and raised their target price for the stock from $264.00 to $320.00 in a report on Thursday, December 21st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $295.30.

Read Our Latest Report on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.